Research programme: cytokine inhibitors - Bioniz

Drug Profile

Research programme: cytokine inhibitors - Bioniz

Alternative Names: BJNZ132-2; BNZ 2; BNZ 3; BNZ132-3

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioniz
  • Class Peptides
  • Mechanism of Action Interleukin 15 receptor antagonists; Interleukin 4 receptor antagonists; Interleukin 9 receptor antagonists; Interleukin receptor common gamma subunit inhibitors; Interleukin-21 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Rheumatoid arthritis
  • Research Autoimmune disorders; Coeliac disease

Most Recent Events

  • 13 Sep 2017 Pharmacodynamics data from a preclinical study in Coeliac disease released by (Company)
  • 13 Sep 2017 Bioniz Therapeutics plans a phase I trial of BNZ 2 for Coeliac disease in 2018
  • 08 Aug 2016 Early research in Autoimmune disorders in USA (unspecified route) (Bioniz Therapeutics pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top